Serina Therapeutics, Inc., a burgeoning force in the biotechnology sector based in Huntsville, Alabama, is thrilled to announce the successful raising of $10 million in funding. This milestone reflects strong confidence from investors in our innovative approach to addressing significant health challenges through our proprietary, clinically-validated polymer technology known as POZ (poly(oxazoline)). The funds will be strategically utilized to advance our research and development initiatives across several promising areas, including vaccines, Parkinson's disease therapies, pain management solutions, oncology projects, and advancements in cannabinoid science. As we continue to pioneer breakthroughs in these vital health areas, this funding will enable us to accelerate our ongoing clinical trials, enhance our product development strategies, and expand our talented team of scientists and researchers. At Serina Therapeutics, we are committed to unlocking the full potential of our polymer technology to create novel treatment options that significantly improve patient outcomes. Our dedicated team is already making strides in key therapeutic areas, and with this new support, we are poised to further amplify our impact on global health. We invite you to learn more about our transformative work and stay updated on our progress by visiting our website at www.serinatherapeutics.com. Together, through innovation and collaboration, we endeavor to make a meaningful difference in the lives of patients and advance the frontiers of medical science.








